Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Bacterial pneumonia cost-effectiveness of therapy
Introduction
Overview
Overview
The use of antibiotics and corticosteroids had proven to be a cost-effective strategy in treating community-acquired pneumonia. Together, they resulted in savings of $142,795 per death averted. In severe cases of community-acquired pneumonia, the combination of antibiotics and corticosteroids yielded savings of $70,587 and had an 82.6% chance of being cost-effective.[1] The cost effectiveness of ceftolozane/tazobactam versus meropenem was also analyzed and resulted in significant savings in early treatment.[2].
References
References
- ↑ Pliakos EE, Andreatos N, Tansarli GS, Ziakas PD, Mylonakis E (2019). “The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia”. Chest. 155 (4): 787–794. doi:10.1016/j.chest.2018.11.001. PMID 30448195.
- ↑ Naik J, Puzniak L, Critchlow S, Elsea D, Dillon RJ, Yang J (2021). “Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia”. Infect Dis Ther. 10 (2): 939–954. doi:10.1007/s40121-021-00436-4. PMC 8034281 Check
|pmc=value (help). PMIDÂ 33837518 Check|pmid=value (help).
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S